Nieuws

PharmExec42 m
Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy
Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...
PharmExec42 m
Blue Cross Blue Shield of Massachusetts Adds Virtual-First Primary Care Option
In an effort to combat the state’s shortage of primary care physicians, Blue Cross Blue Shield of Massachusetts is offering ...
PharmExec42 m
How External Control Arms are Improving Clinical Trials: Q&A with Sujay Jadhav
The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.
PharmExec19u
Viatris’ Meloxicam Formulation Demonstrates Efficacy in Post-Surgical Acute Pain
Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...
PharmExec15u
Impact, Access, and Scale: The Potential of India’s Pharma Market
Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...
PharmExec18u
FDA Announces ‘Aggressive’ AI Implementation Timeline
Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.
PharmExec20u
Creating a Gray Zone in Payer Messaging: Outflanking Comparability
The idea of creating a gray zone in the payer message is to take the onus off of having to heavily discount for equal access ...
PharmExec14u
Quyen Nguyen on Helping Surgeons Preserve Nerve Function in Surgery
Founder and CEO of Alume Biosciences, Quyen Nguyen, MD, PhD, discusses nerve regeneration, nerve visualization and the reason behind what she does at Alume Biosciences.